2 secret growth stocks that could make you a fortune

Royston Wild looks at two shares with hot earnings potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It surprises me not in the slightest that Kainos Group (LSE: KNOS) was marching to fresh record highs above 300p per share on Monday.

The software specialist has the wind in its sales with demand from both new and existing customers continuing to boom, and this was illustrated in half-year trading details released today.

Kainos declared that revenues increased 2% during the six months to September, to £41.4m, a result that pushed adjusted pre-tax profit 1% higher to £7.1m. What really grabbed the eye, however, was news of a demand surge for its ‘Software as a Service’ (or SaaS) bookings which shot to £5.3m from £1.5m.

And in a promising sign for future revenues, the Belfast-based firm said that sales orders almost doubled year-on-year, to £63.4m from £32.6m in the corresponding 2016 period, while its sales backlog leapt to £97.1m, up 43%.

Continental march continues

These interim results underline the exceptional progress Kainos is making both at home and abroad.

In Europe the business boosted the number of clients on its books in the first half to 17 from nine in the same period last year, and Kainos now sources 26% of total sales from international clients versus 19% previously. And the company opened new offices in Frankfurt and Copenhagen (on top of new premises in Birmingham) in the first half in a bold statement of intent.

Tech stocks with stonking momentum often carry a premium and Kainos is no exception. With City analysts predicting a 5% earnings rise in the 12 months ending March 2018 the business sports a forward P/E ratio of 29.8 times.

But I consider this to be a price worth paying given the scope for explosive profits growth later on (indeed, current forecasts points towards a 21% earnings explosion in fiscal 2019 alone).

Meanwhile, the company is also highly cash-generative (the amount of cash on the balance sheet swelled by almost a third in the first half, to £27.3m), providing it with plenty of ammunition to deliver its exciting growth plans.

The drugs DO work

Alliance Pharma (LSE: APH) is another share tipped by the City to enjoy improving earnings momentum beyond the current period.

During 2017, the medicines dispenser is anticipated to report a 2% earnings rise, and to follow this up with a 13% advance next year.

These bubbly predictions come as no surprise as the Chippenham company, much like Kainos, makes impressive progress in international markets.

Alliance Pharma advised in September that, as sales at its Kelo-cote and MacuShield brands jumped 52% and 67% during January-June, group revenues advanced 8% to £50.3m. It said that demand for these products jumped thanks to “a combination of distribution gains in new territories and growth in the rates of sale in existing outlets, stimulated by our increased marketing investment.”

And the business has plenty of financial firepower to keep pushing organic investment, not to mention embark on further exciting bolt-on acquisitions like that of Sinclair Pharma made back in 2015 (cash and cash equivalents jumped £1.8m during the first six months of 2017 to £9m).

These factors, allied to the defensive nature of the pharmaceuticals sector, makes Alliance Pharma a seriously good pick for growth hunters in my opinion. And an extrememly-cheap forward P/E multiple of 15.1 times seals the deal.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »